The stock's fall snapped a four-day winning streak.

Vertex Pharmaceuticals (VRTX) stock has performed strongly since the turn of the year, gaining 14.6% and vastly outperforming the healthcare ...

Analyst Salveen Richter of Goldman Sachs maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report), reducing the price target ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Walmart’s latest brand and logo update has left some social media users baffled. On Jan. 13, the company announced in a press release on its website that it was launching a “comprehensive ...

Vertex Pharmaceuticals Inc. (NASDAQ:VRTX), a leading biotechnology company specializing in cystic fibrosis (CF) treatments, has been making significant strides in expanding its therapeutic ...

Shares of Vertex Pharmaceuticals Inc. VRTX slipped 1.72% to $416.96 Thursday, on what proved to be an all-around rough trading session for the stock market, with the S&P 500 Index SPX falling 0.21 ...

Vertex Pharmaceuticals (NASDAQ: VRTX) is a biotechnology company with a strong track record of success in developing treatments for cystic fibrosis (CF). Vertex is strategically expanding into the ...

It usually doesn't matter if you buy a given stock immediately or two weeks later. Sure, the stock could move up or down but typically not enough to matter all that much. However, there are ...

The most recent trading session ended with Vertex Pharmaceuticals (VRTX) standing at $416.96, reflecting a -1.72% shift from the previouse trading day's closing. The stock's performance was behind ...

In a court filing on Monday, the Department of Health and Human Services fired back at Vertex Pharmaceuticals, standing by a directive that the biotech’s proposed fertility services program to go with ...